abemaciclib + fulvestrant + xentuzumab

The combination of abemaciclib + fulvestrant + xentuzumab is an investigational treatment regimen being studied for advanced breast cancer. This combination brings together three distinct agents with complementary mechanisms of action. Abemaciclib is a selective cyclin-dependent kinase (CDK) 4 & 6 inhibitor that blocks cell cycle progression. Fulvestrant is a selective estrogen receptor degrader (SERD) that works as an endocrine therapy. Xentuzumab is an insulin-like growth factor (IGF) ligand-neutralizing antibody that targets IGF-1 and IGF-2 ligands[1][8]. The rationale for this combination stems from the understanding that activation of the IGF pathway leads to an increase in cyclin D1, providing a scientific basis for combining IGF inhibition (xentuzumab) with CDK4/6 inhibition (abemaciclib)[1]. This combination approach aims to overcome resistance mechanisms in hormone receptor-positive breast cancer. ## Clinical Development A phase Ib study has investigated xentuzumab in combination with abemaciclib and fulvestrant in patients with advanced hormone receptor-positive (HR+) breast cancer. The study included expansion cohorts examining patients with visceral disease (D1) and non-visceral disease (D2)[1]. Preliminary results from this study demonstrated encouraging disease control in patients with advanced HR+ breast cancer with both visceral and non-visceral disease[1]. The recommended Phase II dose was determined to be xentuzumab 1000 mg weekly intravenously plus abemaciclib 150 mg every 12 hours orally[1]. ## Safety Profile The combination therapy appears to have a manageable safety profile. Common adverse events associated with the individual components include: - Abemaciclib: diarrhea, fatigue, neutropenia, and nausea[4][9] - Fulvestrant: injection site reactions, hot flashes, and joint pain - Xentuzumab: Unlike some other IGF pathway inhibitors, xentuzumab does not elevate growth hormones or induce hyperglycemia[8] This combination represents an evolving approach to treating hormone receptor-positive breast cancer, potentially offering a chemotherapy-free option for patients who have progressed on prior endocrine therapy.

Brand names

VerzenioFaslodex

Other names

xentuzumab + abemaciclib + fulvestrant